ClinicalTrials.gg
RecruitingNCT05930210Updated Oct 2, 2025

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

A Phase 3 interventional study of ENERGI-F703 GEL and ENERGI-F703 matched vehicle in Diabetic Foot Ulcer, Foot Ulcer and Diabetes Mellitus, sponsored by Energenesis Biomedical Co., Ltd.. Recruiting at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Energenesis Biomedical Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Diabetic Foot with a site in Taiwan — 3 open to participants now, 5 under way, 1 of them phase 3. Diabetic Foot · Taiwan.

Planned enrollment
5th of 21
230 · median 70
Started
2023
with 2 others
Phase 3
4 of 24
1 open now
Registered
19th of 24
by date
Lead sponsor
2 of 24
Energenesis Biomedical Co., Ltd.

Among the 24 studies in Diabetic Foot with a site in Taiwan, this one is the 5th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 3, and was the 19th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

3 of the 24 studies in Diabetic Foot with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Diabetic Foot with a site in Taiwan, or all of them as a file.
02

Study summary

This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (\<16 cm2 vs ≥16 cm2 ) will be included as a stratification factor. Subjects will be randomized 1:1 to receive ENERGI-F703 GEL or vehicle control using an interactive web response system for randomization to automatically assign a unique subject randomization number. Total duration of the study will be up to 31 weeks including Screening visit (approximately 2 to 3 weeks), double-blind dosing/observation phase (16 weeks), and a safety follow-up of 12 weeks after the last administration of study treatment.

03

Conditions studied

  • Diabetic Foot Ulcer
  • Foot Ulcer
  • Diabetes Mellitus
  • Wound

Keywords

  • Diabetic Foot Ulcer
  • Diabetes Mellitus
  • Wound Healing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be at least 18 years old.
  2. Subject must have diagnosed with diabetes mellitus (DM), eg, currently under DM medication treatment or subjects with naïve DM with duplicated over 6.5% and fasting plasma glucose over 126 mg/dL measured at least 1 week apart before screening.
  3. Subject must have at least 1 cutaneous ulcer on the foot and not healing for at least 4 weeks. The largest diabetic foot ulcer will be selected as target ulcer. If 2 or more ulcers have the largest size, the one with worst grade will be selected. If 2 or more ulcers have the largest size and grade, the one with longest duration will be selected.
  4. The target ulcer is classified as Grade 1 to Grade 2 ulcer according to Wagner Grading System and with ulcer size of 1.5 cm2 to 25 cm2.
  5. Diabetic foot ulcers should be free of any necrosis or infection
  6. Subject has signed the written form
  7. Male subjects must be surgically sterile or commit to the use of a reliable method of (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence for the duration of the study and for 30 days after study treatment administration.
  8. Female subjects are eligible only if all of the following apply:

    • Not pregnant with a negative serum pregnancy test at Screening visit and negative urine pregnancy test within 24 hours before randomization (test not required for females of non-, defined as surgically sterile [eg, hysterectomy or bilateral oophorectomy] or [amenorrheic for at least 1 year])
    • Not lactating
    • Not planning to become pregnant during the study
    • If of childbearing potential, commits to the use of a highly effective method of contraception for the duration of the study and at least 30 days after study treatment administration.

Exclusion criteria

Exclusion Criteria:

  1. History or evidence of osteomyelitis as confirmed by the investigator. An x-ray/pathology assessment of debridement or a probe-to-bone (PTB) test will be used to determine presence of osteomyelitis. However, participants who have a history or evidence of osteomyelitis in other parts of their body are eligible to participate in the study. If the medical history of osteomyelitis was cured by antibiotic therapy, surgery or amputation for more than 1 year, and no recurrence, no finding to the current leg and foot after testing, the participant can be enrolled
  2. With target ulcer size decreased by at least 30% after at least 2 weeks of standard of care-only period between screening and randomization
  3. Subjects with highly exudated wounds which require dressing changes more than 3 times a day may be enrolled, but heavily exudated wounds should not be selected as target ulcers
  4. With poor nutritional status (serum albumin \<2g/dL or prealbumin \<10 mg/dL), poor diabetic control ( >12%), a leukocyte counts \<2,000/mm3, abnormal liver function (, alanine aminotransferase >3 x ) within 21 days before Randomization visit
  5. Requiring treatment with systemic , or chemotherapeutic agents
  6. With known or suspected to any ingredients of study product and vehicle
  7. With coronary heart disease with myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty within 3 months prior to study (patients who have undergone peripheral angioplasty should be excluded unless the surgery was performed at least 30 days prior to screening)
  8. Known or suspected history of drug abuse or a recent history of alcohol abuse (regularly drinks >4 units of alcohol per day: 1 unit = 8 oz. beer, 3 oz. wine, or 1 oz. spirits) within 6 months prior to screening (within 6 months prior to screening includes both drug abuse and alcohol abuse)
  9. History or positive test results for
  10. in the last 2 years, with the exception of non- basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  11. Ankle brachial index \<0.8 or >1.4
  12. Enrollment in any drug trial within 4 weeks before entering this study
  13. With any condition judged by the investigator that entering the trial may be detrimental to the subject -
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    ENERGI-F703 GEL

    ENERGI-F703, topical application, 2 times daily for 16 weeks

    Drug: ENERGI-F703 GEL

  • Placebo comparator
    ENERGI-F703 matched vehicle

    ENERGI-F703 matched vehicle, topical application, 2 times daily for 16 weeks

    Drug: ENERGI-F703 matched vehicle

Interventions

  • DrugENERGI-F703 GEL

    Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.

  • DrugENERGI-F703 matched vehicle

    Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.

06

What researchers measure

Primary outcomes

  1. The ulcer complete closure rate

    Proportion of subjects with a recording of complete ulcer closure at Week 16 (the end of the treatment period) as assessed by the investigator, where such closure is subsequently confirmed at 2 consecutive study visits over a 2-week period (ie, by Week 18). A complete ulcer closure is defined as 100% skin re epithelialization without drainage or dressing requirements.

    Time frame: Weeks 16

Secondary outcomes

  1. The time to ulcer closure

    Time to ulcer closure in weeks, defined as the time from randomization to first record of complete closure, as assessed by the investigator, where complete closure is subsequently confirmed at 2 consecutive study visits over a 2-week period

    Time frame: Weeks 4, 6, 8, 10, 12, 14, and 16

  2. The frequency and severity of adverse events

    Frequency and severity of adverse events (AEs), including treatment emergent AEs, serious AEs, treatment-related AEs, and treatment-related serious AEs

    Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, and 28

  3. The proportion of subjects with complete ulcer closure

    Proportion of subjects with confirmed complete ulcer closure as assessed by the investigator.

    Time frame: Weeks 4, 6, 8, 10, 12, 14, and 16

07

Study locations

24 of 24 sites recruiting
  • A and D Doctor Center
    Miami, Florida 33135, United States
    Recruiting
    • Yordan Orive, Dr. · Contact
  • Bioclinical Research
    Miami, Florida 33155, United States
    Recruiting
    • Rogelio Iglesias, Dr. · Contact
  • Reliant Medical Research
    Miami, Florida 33165, United States
    Recruiting
    • Ramses Vega, Dr. · Contact
  • Advanced Medical Research Institute
    Miami, Florida 33174-3201, United States
    Recruiting
    • Enrique Pelayo, Dr. · Contact
  • New Horizons Research
    Palmetto Bay, Florida 33176, United States
    Recruiting
    • Derrick H. Diaz, Dr. · Contact
  • IACT Health
    Columbus, Georgia 31904, United States
    Recruiting
    • Joseph Surber, Dr. · Contact
  • The Jackson Clinic PA
    Jackson, Tennessee 38305, United States
    Recruiting
    • Kellie Wallace-Wilding, Dr. · Contact
  • Mt. Olympus Medical Research
    Houston, Texas 77095, United States
    Recruiting
    • Julie Lester, Dr. · Contact
  • Wasatch Clinical Research
    Salt Lake City, Utah 84107, United States
    Recruiting
    • Clark Larsen, Dr. · Contact
  • Salem Veterans Affairs Medical Center VAMC
    Salem, Virginia 24153-6404, United States
    Recruiting
    • Aliza Lee, Dr. · Contact
  • Ditmanson Medical Foundation Chia-Yi Christian Hospital
    Chiayi City, Taiwan
    Recruiting
    • Chien-Liang Fang, Dr. · Contact
  • Kaohsiung Medical University Hospital
    Kaohsiung City, Taiwan
    Recruiting
    • Shu-Hung Huang, Dr. · Contact
  • China Medical University Hospital
    Taichung, Taiwan
    Recruiting
    • Hsin-Han Chen, Dr. · Contact
  • Kung Tien General Hospital
    Taichung, Taiwan
    Recruiting
    • Shih-Ting Tseng, Dr. · Contact
  • Taichung Veterans General Hospital
    Taichung, Taiwan
    Recruiting
    • Yiling Lin, Dr. · Contact
  • Chi Mei Medical Center
    Tainan, Taiwan
    Recruiting
    • Chun Chia Chen, Dr. · Contact
  • National Cheng Kung University Hospital
    Tainan, Taiwan
    Recruiting
    • Shin-Chen Pan, Dr. · Contact
  • Cathay General Hospital
    Taipei, Taiwan
    Recruiting
    • Chi-Ming Pu, Dr. · Contact
  • MacKay Memorial Hospital
    Taipei, Taiwan
    Recruiting
    • Ming Feng Tsai, Dr. · Contact
  • National Taiwan University Hospital
    Taipei, Taiwan
    Recruiting
    • Hui-Fu Huang, Dr. · Contact
  • Shin Kong Wu Ho Su Memorial Hospital
    Taipei, Taiwan
    Recruiting
    • Cha-Chun Chen, Dr. · Contact
  • Taipei Veterans General Hospital
    Taipei, Taiwan
    Recruiting
    • Chih-Hsun Lin, Dr. · Contact
  • Tri-Service General Hospital
    Taipei, Taiwan
    Recruiting
    • Hao-Yu Chiao, Dr. · Contact
  • Linkou Chang Gung Memorial Hospital
    Taoyuan, Taiwan
    Recruiting
    • Jiun-Ting Yeh, Dr. · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2025, 31 months after the start.

Of 18 phase 3 interventional studies under Diabetic Foot, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Jul 5, 2023
StartActual
May 30, 2023
Primary completionEst.
Dec 30, 2025
CompletionEst.
Mar 31, 2026
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05930210
Responsible party
Sponsor
First posted
Jul 5, 2023
Start date
May 30, 2023
Primary completion
Dec 30, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Oct 2, 2025

Study contacts

Yifang Cheng, PhD
Contact
ct@energenesis-biomedical.com
+886-2-26270835

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion